Moderna vaccine 94.5% effective in second breakthrough
In this file photo a view of Moderna headquarters is seen on May 8, 2020 in Cambridge, Massachusetts. US biotech firm Moderna on May 18, 2020 reported "positive interim" results in the first clinical tests of its vaccine against the new coronavirus performed on a small number of volunteers. The vaccine appeared to produce an immune response in eight people who received it, of the same amplitude as that observed in people infected with the virus, the company said, adding that phase 3 trials with a large number of volunteers would begin in July.
AFP/MADDIE MEYER/GETTY IMAGES NORTH AMERICA
Moderna vaccine 94.5% effective in second breakthrough
Issam Ahmed (Agence France-Presse) - November 16, 2020 - 9:06pm

WASHINGTON, United States — US biotech firm Moderna on Monday announced its experimental vaccine against COVID-19 was 94.5% effective, marking a second major breakthrough in the vaccine hunt.

Moderna released early results from a clinical trial with more than 30,000 participants, after US pharmaceutical company Pfizer and its German partner BioNTech last week said their vaccine was 90% effective. 

Both vaccine frontrunners are based on a new platform called messenger RNA, which is faster to produce than traditional vaccines and effectively turn human cells into vaccine factories.

"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," said Stephane Bancel, Moderna's CEO.

The company plans to submit applications for emergency approval in the US and around the world within weeks, and says it expects to have approximately 20 million doses ready to ship in the US by the end of the year.

Global infections from COVID-19 have soared past 54 million with more than 1.3 million deaths since the virus emerged in China late last year.

The Moderna vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and the preliminary results are based on 95 volunteers of the 30,000 who fell ill with COVID-19.

Of the 95, 90 had been in the trial's placebo group, and five in the group that received the drug, called mRNA-1273.

'Tremendously exciting'

There were 11 people who fell severely ill, all of whom were in the placebo group.

The vaccine was well tolerated, with the majority of side-effects classed as mild or moderate.

After the first dose, about three percent of people had injection site pain classed as severe. 

Among side-effects classed as severe after the second dose, about 10 percent had fatigue, nine percent had muscle pain, five percent had joint pain or headaches, four percent had other pain and two percent had redness at the injection site.

These adverse events were "short lived," according to a statement.

"This news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months," said Peter Openshaw, a professor of experimental medicine at Imperial College London.

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius (36 degrees Fahrenheit to 46 degrees Fahrenheit) for 30 days.

The company added it could be kept in long-term storage at standard freezer temperatures of -20 degrees Celsius (-4 degrees Fahrenheit) for up to six months.

Pfizer's vaccine, on the other hand, needs to be stored in deep-freezer conditions which could complicate supply chain logistics, particularly in less developed countries.

It is not yet clear how long lasting the protection will be from either the Moderna or Pfizer vaccines, nor how well they work for the elderly, the age-group at highest risk from COVID-19.

COVID-19 VACCINES MODERNA NOVEL CORONAVIRUS
As It Happens
LATEST UPDATE: November 23, 2020 - 5:20pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

November 23, 2020 - 5:20pm

European stock markets opened firmer Monday, buoyed as positive news on another coronavirus vaccine trial helped offset concerns over soaring case numbers, dealers said.

In London, the FTSE 100 index of leading shares was up 0.5 percent at 6,382.36 points.

In the Eurozone, the Paris CAC 40 gained nearly one percent to 5,543.83 points and the Frankfurt DAX put on 0.6 percent to 13,219.25 points.

Shortly before the markets opened, British drugs group AstraZeneca and the University of Oxford said their jointly-developed vaccine against COVID-19 has shown "an average efficacy of 70 percent" in trials, and up to 90 percent in one dosage combination. — AFP

November 23, 2020 - 10:34am

The United States hopes to begin coronavirus vaccinations in early December, a top government health official said Sunday, the latest positive news to emerge even as cases surge across the worst-hit nation and elsewhere around the globe.

The beginning of vaccinations could be a crucial shift in the battle against a virus that has claimed more than 1.4 million lives worldwide, including 255,000 just in the US, since emerging from China late last year.

Encouraging results from vaccine trials have bolstered hopes for an end to the pandemic, as nations reimpose restrictions and lockdowns that slowed the spread earlier this year but turned lives and economies upside down across the globe. — AFP

November 19, 2020 - 8:31pm

A leading COVID-19 vaccine candidate has shown to safely produce a robust immune response in healthy older adults, its British makers said Thursday as it released its phase 2 trial results.

The vaccine, developed by the University of Oxford and AstraZeneca, produced fewer side effects in people aged 56 and over than in younger people — a significant finding given that COVID-19 disproportionately causes severe illness among seniors. 

The manufacturers said the vaccine was undergoing larger, more comprehensive phase 3 trials to confirm the results. — AFP

November 18, 2020 - 8:34pm

The biotech company Pfizer says Wednesday that a completed study of its experimental COVID-19 vaccine showed it is 95% effective.

Pfizer says the vaccine had no serious side effects and that the company will apply for emergency use authorization from US regulators within a matter of days.

"The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic," says Pfizer CEO Albert Bourla. — AFP

November 18, 2020 - 9:34am

Pfizer is "very close" to applying for an emergency use approval for its COVID-19 vaccine after collecting safety data to submit to US regulators, the company's CEO said Tuesday, according to a report. 

The pharmaceutical giant announced last week preliminary results from a late-stage clinical trial showing the injections it had co-developed with Germany's BioNTech was more than 90 percent effective after the second dose.

"We are very close to submitting for an emergency use authorization," Albert Bourla says. "We will announce it as soon as we are doing it." 

— AFP

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with